• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Qingling,FU Shanshan,TAN Chunjiang.The effects of Xinshuitong Capsule on NT-proBNP, cTNI and coagulation indices in rats with chronic heart failure[J].Journal Of Pharmaceutical Research,2019,38(6):318-321,342[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3322times   Download 3224次 QR Code for this article
Scan with your phone!
心水通胶囊水提物对慢性心衰大鼠NT-proBNP、cTNⅠ、凝血指标的影响
汪庆玲1,傅珊珊1,谭春江2,3
Font:Larger+|Default|Smaller-
(1.福建中医药大学药学院,福建 福州 350122;2.福建中医药大学中西医结合研究院,福建 福州 350122;3.福建省中西医结合老年性疾病重点实验室,福建 福州 350122)
摘要:
目的 研究心水通胶囊水提物(XST)对慢性心衰大鼠N-端脑利钠肽前体(NT-proBNP)、心肌肌钙蛋白(cTNⅠ)、心功能及凝血指标的影响。方法 阿霉素构建慢性心衰大鼠模型,并用不同浓度心水通胶囊水提物干预心衰大鼠。在给药前、给药15d、给药30d三个阶段分别检测每组大鼠心功能。给药30 d后,检测血清N-端脑利钠肽前体、心肌肌钙蛋白、凝血指标浓度,HE染色观察心肌细胞病理变化。结果 与模型组比较,心水通胶囊水提物中、高剂量组LVIDs和LVIDd明显降低,射血分数(LVEF)明显升高(P<0.01),血清N-端脑利钠肽前体、心肌肌钙蛋白和纤维蛋白原(FIB)浓度显著降低(P<0.01),凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和凝血酶时间(TT)水平显著升高(P<0.01),且高剂量组给药30 d后LVIDs和LVIDd降低最显著,射血分数升高最显著(P<0.05);同时心水通胶囊水提物能改善心衰大鼠心肌细胞的病理性肥大、变性和坏死。结论 心水通胶囊水提物能剂量依赖性降低心衰大鼠血清N-端脑利钠肽前体、心肌肌钙蛋白浓度,改善高凝血和心功能,提高心衰大鼠的存活率。
关键词:  心水通胶囊  慢性心衰  心功能  凝血
DOI:10.13506/j.cnki.jpr.2019.06.002
基金项目:福建省科技厅对外合作重点项目(No.201410012);福建省卫生和计划生育委员会(No.2017-CX-39)
The effects of Xinshuitong Capsule on NT-proBNP, cTNI and coagulation indices in rats with chronic heart failure
WANG Qingling1,FU Shanshan1,TAN Chunjiang2,3
(1.College of Pharmacy, Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;2.Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;3.Fujian Key Laboratory of Integrated Medicine for Geriatric Diseases,Fuzhou 350122,China)
Abstract:
Objective To evaluate the effects of Xinshuitong Capsule(XST) on NT-proBNP, cTNI, cardiac function and coagulation indices in rats with chronic heart failure(CHF).Methods A rats model of CHF was established by using Adriamycin, followed by the intervention of experimental rats with XST at different concentrations.Cardiac function was measured before administration, as well as 15 days and 30 days after administration,respectively.After 30 days of administration, the concentration of serum NT-proBNP、cTNI and coagulation indices were detected, and the pathological changes of cardiomyocytes were observed by HE staining.Results LVIDs and LVIDd were significantly decreased, LVEF was obviously increased(P<0.01),serum NT-proBNP,cTNI,and FIB concentrations were evidently decreased(P<0.01), while PT, APTT and TT levels were remarkably increased in moderate and high dose groups of XST(P<0.01),compared with the model group. And there were the most significant trends in the decrease of LVIDs and LVIDd, as well as the increase in LVEF in the high dose group after 30 days of administration(P<0.05).HE staining showed that XST can improve the pathological hypertrophy, degeneration and necrosis of cardiomyocytes in rats with CHF.Conclusion XST can reduce the concentration of NT-proBNP and cTNI in dose dependent, and improve hypercoagulation, cardiac function, and the survival rate in rats with CHF.
Key words:  Xinshuitong Capsule  Chronic Heart Failur  Heart Function  Coagulation
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.